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Introduction: The availability of mice transgenic for the human HER2 gene (huHER2) and prone to the development of
HER2-driven mammary carcinogenesis (referred to as FVB-huHER2 mice) prompted us to study active immunopreventive
strategies targeting the human HER2 molecule in a tolerant host.
Methods: FVB-huHER2 mice were vaccinated with either IL-12-adjuvanted human HER2-positive cancer cells or DNA
vaccine carrying chimeric human-rat HER2 sequences. Onset and number of mammary tumors were recorded to
evaluate vaccine potency. Mice sera were collected and passively transferred to xenograft-bearing mice to assess their
antitumor efficacy.
Results: Both cell and DNA vaccines significantly delayed tumor onset, leading to about 65% tumor-free mice at
70 weeks, whereas mock-vaccinated FVB-huHER2 controls developed mammary tumors at a median age of 45 weeks.
In the DNA vaccinated group, 65% of mice were still tumor-free at about 90 weeks of age. The number of mammary
tumors per mouse was also significantly reduced in vaccinated mice. Vaccines broke the immunological tolerance to
the huHER2 transgene, inducing both humoral and cytokine responses. The DNA vaccine mainly induced a high and
sustained level of anti-huHER2 antibodies, the cell vaccine also elicited interferon (IFN)-γ production. Sera of DNA-
vaccinated mice transferred to xenograft-carrying mice significantly inhibited the growth of human HER2-positive
cancer cells.
Conclusions: Anti-huHER2 antibodies elicited in the tolerant host exert antitumor activity.Introduction
The ErbB-2 oncogene (HER2 in humans) is amplified
and overexpressed in 20% to 30% of aggressive breast
cancers, as well as in fractions of tumors of the ovary,
stomach and others [1-3]. HER2 codes for a membrane
tyrosine kinase; therefore, it can be targeted by
antibodies and immune effector cells. Its oncogenic
function, coupled to membrane expression, led to the
definition of an oncoantigen [4,5], that is, an oncogene
which is also a tumor-associated antigen that can be* Correspondence: patrizia.nanni@unibo.it
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HER2-targeted therapies based on monoclonal anti-
bodies (such as trastuzumab and pertuzumab) and on
small-molecule inhibitors are in widespread clinical use.
Even though generally well-tolerated, such treatments
have some drawbacks: cost, need for continuous
treatment, increased risk of cardiac toxicity and, mainly,
frequent onset of resistance to therapy. The search for
anti-HER2 vaccines able to break the patient’s tolerance
toward HER2 is being pursued to elicit effective anti-
tumor immune responses and immunological memory
[6-8]. Anti-HER2 vaccines could be employed in a
therapeutic setting, even in combination with other
therapies, but most likely could be used in an adjuvant
setting to prevent the development of metastases or tontral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cinoma [9].
Preclinical studies on the prevention of mammary car-
cinogenesis driven by the rat HER2 gene (normal or mu-
tated) have shown that several immune approaches can
hamper the neoplastic process, ranging from the admin-
istration of cytokines, such as interleukin 12 (IL-12)
[10], to active vaccination approaches [4,5]. Cell vaccines
have shown high potency only when coupled with strong
adjuvant stimuli (such as allogeneic stimulation and IL-12)
[11,12]. Cytokines other than IL-12 were found to be far
less efficient [12]. The adjuvant effect of IL-12 in cell vac-
cine also was found to be effective in curing minimal re-
sidual disease [13]. DNA vaccines also have proved to be
highly effective [14-16].
Although passive targeting of the human HER2 (huHER2)
homologue—for example, with antibodies—can easily
be studied in vivo against human HER2-positive can-
cers grown as xenografts in immunodeficient mice, ac-
tive immune approaches require immunocompetent mice
tolerant to huHER2. Some huHER2 transgenic lines
[17,18] were found not to develop spontaneous mammary
tumors and were used only in vaccination challenge ex-
periments to study the efficacy of anti-HER2 vaccines.
Tumor-prone mice transgenic for huHER2, obtained by
Finkle and co-workers [19], allow the study of immuno-
prevention of autochthonous tumor onset through vac-
cines targeting the normal huHER2 molecule. These mice
(referred to as FVB-huHER2 herein) carry a wild-type
huHER2 gene under the control of the mouse mammary
tumor virus (MMTV) promoter and show spontaneous
development of mammary tumors in most female mice in
the second semester of life. A few data have been reported
on the prevention of tumors of these mice by passive
transfer of antibodies [19] and by an anti-idiotype active
immune approach [20].
In our present study, we used FVB-huHER2 transgenic
mice to study anti-huHER2 vaccine strategies (a xenogeneic
whole-cell vaccine and a DNA human/rat chimeric vac-
cine) to break tolerance to huHER2. We had two aims:
(1) to evaluate vaccine efficacy in the immunopreven-
tion of huHER2-driven mammary tumors, and (2) to
study whether anti-HER2 antibodies resulting from a
break of tolerance could inhibit human tumors growing
as xenografts.
Methods
Mice
FVB-huHER2-transgenic mice were obtained from Genen-
tech (line MMTV.f.hu.HER2#5(Fo5) on FVB background;
South San Francisco, CA, USA) [19]. They carry the full-
length, normal huHER2 gene under the control of the
MMTV promoter. FVB-huHER2 mice were bred in our
animal facilities and genetically screened by PCR usinga primer set specific to human growth hormone exons
4 and 5, which are included in the transgene backbone,
as reported previously [19]. Mice were inspected weekly
by palpation. Progressively growing masses larger than
0.3 cm in diameter were scored as tumors. The mice
were killed when the diameter of one of the tumors
exceeded 1.7 cm. Nontransgenic FVB/NCrl (FVB) fe-
male mice were purchased from Charles River Labora-
tories (Calco, Como, Italy). For xenograft experiments,
we used the immunodeficient Rag2−/−;Il2rg−/− mice
(kindly provided by Drs Nomura and Ito, Central Insti-
tute for Experimental Models, Kawasaki, Japan) [21]. In
vivo experiments were performed in compliance with
the Italian and European guidelines and were approved
by the Institutional Review Board of the University of
Bologna.
Cells
The HER2-positive human ovarian carcinoma cell line
SK-OV-3 was cultured in RPMI 1640 medium (Invitro-
gen, Milan, Italy) supplemented with 10% fetal bovine
serum (FBS) and maintained at 37°C in a humidified
atmosphere with 5% CO2. Other human cell lines with
different HER2 expression were used as well: MDA-
MB-453 (breast cancer origin, medium to high HER2
expression) [21], MCF-7 (breast cancer origin, low
HER2 expression) and SJ-RH4 (rhabdomyosarcoma,
null HER2 expression) [22]. We established a cell line,
which we refer to as syn-HER2, from a mammary carcinoma
of a FVB-huHER2 mouse. This cell line showed high
expression of huHER2 and tumorigenicity in syngeneic
hosts.
Plasmids
Chimeric human/rat HER2 plasmid electroporated vac-
cine (HuRT), previously described in detail [16], derived
from pVAX1 (Invitrogen), encodes a chimeric protein in
which the first 390 extracellular NH2-terminal residues
are from huHER2 and the remaining extracellular and
transmembrane residues from rat HER2/neu. Empty vec-
tor pVAX1 was used as an experimental control. Large-
scale production and purification of the plasmids were
performed with EndoFree Plasmid Giga kits (QIAGEN,
Valencia, CA, USA) as previously reported [15].
Cytokine and vaccine treatments
The cell vaccine was formulated as mitomycin C–treated
huHER2-overexpressing human cancer cells (SK-OV-3)
associated with exogenous administration of recombin-
ant murine IL-12 to provide the specific huHER2 anti-
gen combined with adjuvants (xenogenicity and IL-12).
The cell vaccination schedule was reported previously.
Briefly it was based on a 4-week cycle. During the first
2 weeks, mice received four twice-weekly intraperitoneal
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(mitomycin C–treated [23]) SK-OV-3 cells in 0.4 ml of
phosphate-buffered saline (PBS). During the third week,
mice received daily i.p. administration of murine IL-12
followed by 1 week of rest [11]. The IL-12 dose was
50 ng per day in the first vaccination cycle and 100 ng
per day in subsequent cycles. Vaccination cycles were
repeated for the entire lifetime of the mouse. Control
groups consisted of untreated mice and mice treated
with vehicle alone (PBS). Mice were monitored weekly
for mammary tumor onset.
DNA vaccination consisted of two intramuscular (i.m.)
injections of 50 μg of plasmid diluted to a final volume
of 40 μl per mouse in final concentrations of 0.9% NaCl
and 6 mg/ml polyglutamate. Anesthetized mice received
the injection of DNA vaccine into the tibial muscles
(20 μl in each muscle) through a 28-gauge needle syr-
inge. Immediately thereafter the muscle tissues were
subjected to electroporation, consisting of two square
wave, 25-ms, 375 V/cm pulses generated with a T830
electroporator (BTX, San Diego, CA, USA). The vaccin-
ation course consisted of two i.m. injections repeated at
14-day intervals according to the following schedule:
first week, DNA vaccine; second week, rest; third week,
DNA vaccine; and fourth to tenth weeks, rest [15]. Vac-
cinations were repeated for the entire lifetime of the
mouse. Control groups consisted of untreated mice or
mice treated with pVAX1 empty vector.Antibody response
Serum samples from vaccinated and control mice were
collected periodically and stored frozen at −80°C. Anti-
huHER2 antibodies were then detected by a specific
enzyme-linked immunosorbent assay (ELISA) as de-
scribed previously [15]. Thermo Scientific Immunoplate
Nunc Maxisorp 96-well microplates (Cole-Parmer North
America, Vernon Hills, CA, USA) were coated with the
extracellular domain of huHER2 molecule, at 1 μg/ml and
100 μl/well, by overnight incubation. After blocking and
washing incubations, sera at 1:250 to 1:500 dilutions were
added. Secondary goat anti-mouse immunoglobulin G
(IgG)-peroxidase conjugate antibody (1:12,000 dilution;
Calbiochem, San Diego, CA, USA) was added after plate
washing. Next, 100 μl of 3,3′,5,5′-tetramethylbenzidine per-
oxidase substrate were added (Thermo Scientific, Rockford,
IL, USA). After the reaction was stopped with 0.18 M
sulfuric acid, absorbance was measured at 450 nm and
620 nm using an ELISA microreader (Tecan Systems, San
Jose, CA, USA). A standard curve with anti-huHER2 mur-
ine monoclonal antibody clone 4D5 (Genentech) was run
in parallel (0.04 to 30 ng/ml). Anti-HER-2/neu total anti-
bodies and subclasses were studied by flow cytometry as
reported previously [11].Cytokine production
Spleen cells were collected from vaccinated and control
mice after at least three vaccination cycles. Interferon γ
(IFN-γ) production by spleen mononuclear cells was
evaluated after in vitro culture for 6 days alone (spontan-
eous release) or in the presence of proliferation-blocked
huHER2-positive cells (at a 10:1 lymphocyte/tumor cell
ratio) in RPMI 1640 medium supplemented with 10%
FBS and recombinant IL-2 (20 U/ml) as described pre-
viously [11]. HuHER2-positive cells used were a cell
line derived from mammary cancer of FVB-huHER2
(referred to as syn-HER2) and human SK-OV-3 cells
(referred to as xeno-HER2). Culture supernatants were
collected, and murine IFN-γ was quantified by ELISA
(R&D Systems, Minneapolis, MN, USA).
Whole-mount tissue sections
Whole-mount sections of all mammary glands were pre-
pared as described previously [24]. Briefly, mouse skin
was removed and fixed overnight in 10% buffered forma-
lin. Mammary fat pads were scored into quarters, gently
scraped from the skin and immersed in acetone over-
night. After rehydration, samples were stained with ferric
hematoxylin (Sigma-Aldrich, Milan, Italy), dehydrated in
increasing concentrations of alcohol, cleared with limonene
and stored in methyl salicylate (Sigma-Aldrich). Digital
pictures were taken with a Nikon COOLPIX 995 camera
(Nikon Europe, Turin, Italy) mounted on a stereoscopic
microscope (Leica MZ6; Leica Microsystems, Buffalo
Grove, IL, USA).
Immunohistochemistry
Optimal cutting temperature compound–embedded sec-
tions were immunostained with the following antibodies:
CD4 (rat anti-mouse; BD Biosciences Pharmingen, San
Diego, CA, USA), CD8 (rat anti-mouse; BD Biosciences
Pharmingen), CD11b (rat anti-mouse; BD Biosciences
Pharmingen), CD68 (rat monoclonal antibody; Abcam,
Cambridge, UK), FoxP3 (rat anti-mouse; eBioscience,
San Diego, CA, USA), Gr-1 (rat anti-mouse; BD Biosci-
ences Pharmingen), B220 (rat anti-mouse; BD Biosci-
ences Pharmingen) and CD31/105 (rat anti-mouse; BD
Biosciences Pharmingen) for vessels. After being washed,
the sections were overlaid with appropriate secondary
antibodies. Immunostaining was developed using the
chromogen 3-amino-9-ethylcarbazole in the LabVision
Ready-to-Use AEC Substrate System (Thermo Scientific)
or a standard streptavidin biotinylated alkaline phosphat-
ase method (Thermo Scientific).
HER2 signaling
Cells were lysed with Novagen PhosphoSafe Extraction
Reagent (EMD Millipore, Milan, Italy) plus phosphatase
and protease inhibitors (purchased from Sigma-Aldrich)
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Nuclei were removed by centrifugation at 12,000 × g at
4°C for 15 minutes, and the protein concentration in
the supernatants was determined by DC Protein Assay
(Bio-Rad Laboratories, Milan, Italy) using bovine serum
albumin as the standard. Proteins were separated on an
8% polyacrylamide gel (20 μg of total lysate), then
transferred to polyvinylidene difluoride membranes
(Bio-Rad Laboratories). After blocking with PBS con-
taining 0.1% Tween 20 plus 5% nonfat dry milk for
2 hours at room temperature, membranes were incubated
overnight at 4°C with primary antibodies diluted in block-
ing buffer. Anti-c-ErbB2/c-Neu (Ab3) mouse monoclonal
antibody (3B5) (0.2 μg/ml; Calbiochem/EMD Chemicals,
San Diego, CA, USA), anti-p-Neu (Tyr 1248)-R rabbit
polyclonal antibody (0.2 μg/ml sc-12352-R; (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-AKT
rabbit polyclonal antibody (1:1,000 dilution; 9272),
anti-phospho-Akt (Ser473) (D9E) XP rabbit monoclo-
nal (1:1,000 dilution; 4060) (all purchased from Cell
Signaling Technology, Danvers, MA, USA) and anti-
actin rabbit antibody (1 μg/ml; Sigma-Aldrich) were
used as primary antibodies. After incubation with the re-
spective horseradish peroxidase–labeled secondary anti-
bodies (Santa Cruz Biotechnology), protein presence was
revealed by chemiluminescence reaction (LiteAblotplus
chemiluminescence substrate; EuroClone, Milan, Italy).Adoptive transfer of spleen cells from vaccinated mice
Mice received two vaccinations with HuRT-DNA or
pVAX1 (as reported above) at 2-week intervals, then spleen
cells were collected and coinjected subcutaneously (s.c.)
with Syn-HER2 cancer cells. Tumor diameter was mea-
sured twice weekly with digital calipers. Tumor volumes
were calculated as π/6•[√(a•b)]3, where a =maximal tumor
diameter and b =major tumor diameter perpendicular to a.Figure 1 Induction of anti-huHER2 antibody response by human
cancer cell vaccines with different levels of HER2 membrane
expression. Nontransgenic mice received one cycle of vaccination
(cells and recombinant interleukin 12) as reported in Methods. The
x-axis represents the HER2 expression level (cytofluorometric evaluation
by mean fluorescence intensity (MFI) measured in arbitrary units) of
cells used for vaccinations, and the y-axis represents the corresponding
level of anti-huHER2 antibodies elicited by vaccinations. The dashed
line shows the enzyme-linked immunosorbent assay detection
sensitivity limit. Data shown are the mean and SEM from five mice per
group. huHER2, human HER2 gene.HER2-positive xenograft therapy
The therapeutic activity of anti-huHER2 antibodies elic-
ited by HuRT-DNA in FVB-huHER2 mice was tested
against HER2-positive human xenografts. Groups of
five to seven Rag2−/−;Il2rg−/− female mice received i.p.
injections of 2 × 106 SK-OV-3 ovarian carcinoma cells.
Starting on the following day, mice received i.p. 200 μl
of pooled sera from mice vaccinated with HuRT-DNA.
Treatment was repeated on days 3, 7 and 14 afterward.
Control mice received sera pooled from control FVB-
huHER2 mice (untreated or pVAX1-treated). The mice
were killed 5 weeks after cancer cell injection. Accurate
necropsy was performed, and intraperitoneal tumor
masses were collected and weighed to quantify thera-
peutic efficacy.Statistical analysis
The logrank Mantel–Haenszel test was used to compare
tumor-free survival curves. Student’s t-test and a Wilcoxon
nonparametric test were used for other comparisons.
Results
HER2-transgenic model and vaccines
The mouse model of mammary carcinogenesis driven
by the wild-type huHER2 oncogene (referred to as
FVB-huHER2 herein) [19] is characterized by tumor
onset after more than 40 weeks of age and by low num-
bers of neoplastic mammary glands, similar to what
happens in mice transgenic for the wild-type rat HER2
homologue [10,11,25].
From previous experiments on immunoprevention of
rat neu-driven carcinogenesis [5], we learned that both a
whole-cell vaccine and a DNA vaccine can be effective,
and that efficacy depends on vaccine conditions and the
level of antibody response [12,23]. Therefore, we per-
formed preliminary experiments to choose vaccines and
conditions able to induce the highest anti-huHER2 anti-
body response.
To choose the best whole-cell vaccine, we vaccinated
nontransgenic mice with a panel of human tumor cell
lines with different HER2 expression, using IL-12 as a
biological adjuvant. The level of anti-huHER2 antibodies
elicited was proportional to the log-transformed mem-
brane expression of HER2 (Figure 1). To maximize anti-
body induction in tolerant FVB-huHER2-transgenic mice,
we therefore chose the SK-OV-3 cell line as the cell vaccine
(that is, the highest inducer of anti-huHER2 antibodies
Table 1 Vaccination of FVB-huHER2 mice started at
different ages: effect on induction of anti-huHER2
antibody levels at 4 weeks after first vaccinationa
Vaccine Start of
vaccination
(weeks of age)
Number
of mice
Anti-huHER2
antibodies (ng/ml),
mean ± standard error
HER2-cell 5 to 7 9 1,121 ± 347
8 to 12 6 720 ± 327
18 to 20 4 692 ± 243
24 to 26 6 1,107 ± 123
HuRT-DNA 11 to 15 6 1,671 ± 440*
18 to 20 6 5,297 ± 1,284
24 to 26 5 667 ± 277*
aFVB-huHER2, FVB mice transgenic for huHER2; huHER2, human HER2 gene.
*P = 0.02 vs. HuRT-DNA at 18 to 20 weeks (Student’s t-test).
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the HER2-cell vaccine). DNA cell vaccine was a chimeric
human/rat HER2 construct (HuRT-DNA vaccine), which
was previously reported to be a good inducer of anti-HER2
antibodies [16,18].
Regarding the vaccination schedule, we previously
found in rat HER2/neu-transgenic mice that a fast, high
induction of anti-HER2/neu antibodies was required toa
c
Figure 2 Inhibition of mammary carcinogenesis in FVB-huHER2 mice
group by Mantel-Haenszel analysis). (b) Tumor multiplicity (mean number ±
(c) Whole-mount section of the fourth mammary gland of control (left panel)
Mock: The results in the control groups (untreated, vehicle and pVAX1) were
HER2-cell vaccine (n = 8); HuRT-DNA vaccine (n = 12). FVB-huHER2, FVB mice t
electroporated vaccine.obtain the highest cancer immunopreventive activity
[23,26]. To set up the optimal time to start vaccination
of transgenic FVB-huHER2 mice, we vaccinated mice of
different ages and examined the anti-huHER2 antibody
levels obtained 4 weeks after the first vaccination
(Table 1). We found that the response to the HuRT-
DNA vaccine was dependent on the age at first vaccin-
ation, with the maximum level reached at 18 to 20 weeks
of age. The humoral response to HER2-cell vaccine
reached levels lower than DNA vaccine and was not re-
lated to age. Therefore, we decided to start HER2-cell
vaccine treatment as soon as possible (6 weeks of age)
and HuRT-DNA vaccine at the optimal time for anti-
huHER2 antibody induction (18 weeks of age).Immunoprevention of huHER2-driven mammary
carcinoma
To prevent the onset of mammary carcinoma, FVB-
huHER2 mice received lifelong vaccinations with HER2-
cell or HuRT-DNA anti-human HER2 vaccines. The
experimental end points were the age at the onset of the
first mammary carcinoma and the total number of tu-
mors per mouse.b
by anti-HER2 vaccines. (a) Tumor-free survival (*P < 0.05 vs. mock
SEM) (*P < 0.05 vs. mock vaccination group by Student’s t-test).
or vaccinated (right panel) mice at 60 weeks of age. L = lymph node.
not significantly different, and the data were cumulated (n = 31).
ransgenic for huHER2; HuRT, chimeric human/rat HER2 plasmid
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huHER2 mice, with about 65% of mice being tumor-free
at 70 weeks of age (P < 0.05 by logrank Mantel–Haenszel
test), whereas the median latency time of tumors was
45 weeks in mock-vaccinated mice (Figure 2a). In HuRT-
DNA-vaccinated mice, even at about 90 weeks, 65% of
mice were tumor-free. Vaccines significantly decreased
tumor multiplicity compared to controls (P < 0.05 by
Student’s t-test) (Figure 2b). The median times from
tumor onset to death were 11.5 weeks for mock-
vaccinated mice, 16 weeks for HER2-cell-vaccinated
mice and 14.5 weeks for HuRT-DNA-vaccinated mice.
The data show that vaccinations almost doubled the
lifespans of the mice.
Whole-mount tissue section analysis of mammary
glands showed multifocal carcinogenesis in control mice
(Figure 2c, left) with focal huHER2 expression in ducts
fostering the occurrence of neoplastic lesions, whereas
mammary glands of HuRT-DNA-vaccinated mice were
almost devoid of neoplastic lesions (Figure 2c, right).Figure 3 Immunohistochemical staining of tumors grown in mock-, HE
for the indicated molecule. Original magnification × 400. HuRT, chimeric humImmune responses elicited by vaccines
The immunohistochemical staining of tumors grown in
control and vaccinated mice showed a marked increase
of lymphocyte infiltration in the two vaccinated groups.
Figure 3 shows that though only a few CD4+ and CD8+
lymphocytes and rare Foxp3 cells were present at the
edges of control group tumors, numerous CD4+ and
CD8+ cells were found in both the external and inner
parts of the tumors in vaccinated groups. Interestingly, the
HER2-cell-vaccinated group also showed a significant in-
crease in Foxp3-positive regulatory T cells (Figure 4). No
significant differences were noted in the myeloid infiltrate
(CD11b+, CD68+ and Gr-1+) or in B cells (Figure 4).
To functionally assess the overall activity of leukocyte
responses elicited by anti-HER2 vaccines, we coinjected
syn-HER2 tumor cells and spleen cells into syngeneic
mice. In this adoptive transfer experiment, the splenocytes
of HuRT-DNA vaccinated mice delayed tumor growth in
comparison to splenocytes of mock-vaccinated (pVAX1)
mice (Figure 5).R2-cell- and HuRT-DNA-vaccinated mice. Red staining shows positivity
an/rat HER2 plasmid electroporated vaccine.
Figure 4 Semiquantitative analysis of the populations infiltrating tumors grown in mock-, HER2-cell- and HuRT-DNA-vaccinated mice.
Mean and SEM of three to nine mice per group. *P < 0.05 vs. mock-vaccinated control group by Student’s t-test. HuRT, chimeric human/rat HER2
plasmid electroporated vaccine.
De Giovanni et al. Breast Cancer Research 2014, 16:R10 Page 7 of 11
http://breast-cancer-research.com/content/16/1/R10Both vaccines broke the tolerance toward huHER2 and
rapidly elicited anti-huHER2 humoral responses, with
some differences in potency and kinetics between vac-
cines, which are in agreement with preliminary experi-
ments. The HuRT-DNA vaccine elicited a very high,
steady level of antibodies, reaching 20 to 50 μg/ml, as
shown by a specific ELISA (Figure 6), whereas antibodies
induced by the HER2-cell vaccine peaked at 12 weeks and
decreased thereafter with a plateau at about 1 μg/ml.
IFN-γ production by spleen cells was studied in vacci-
nated and control mice (Figure 7). Splenocytes of HER2-
cell-vaccine-treated mice spontaneously released IFN-γ,
the amount of which was significantly increased after
in vitro culture with syngeneic HER2-positive cells (syn-
HER2) and reached very high levels after culture with
vaccine cells (xeno-HER2). Such high in vitro response
to xeno-HER2 cells could be also attributed to a xeno-
geneic reaction to human antigens unrelated to HER2,
thus mimicking the IFN-γ burst that happened in vivo
after each vaccination cycle. Splenocytes from HuRT-Figure 5 Activity of adoptively transferred spleen cells from mice vac
the subcutaneous growth of syn-HER2 cancer cells (Winn test). A 40:1
mice per group. *P < 0.05 vs. pVAX1-vaccinated group by Student’s t-test. HDNA vaccinated mice did not release IFN-γ, and a low
IFN-γ response to huHER2-positive cells was observed.
The DNA vaccine was as effective as (or even more ef-
fective than) the HER2-cell vaccine for immunopreven-
tion, even in the absence of an IFN-γ burst, thus
suggesting that a high level of anti-HER2 antibodies
could be sufficient to prevent tumor onset.
To further investigate the antitumor activity of anti-
huHER2 antibodies, we focused on the HuRT-DNA vac-
cine because it induced higher titers of anti-huHER2
antibodies and was devoid of extraneous xenogeneic
stimuli that could elicit responses against antigens other
than HER2. The level of anti-huHER2 antibodies after
the first vaccination cycle was used to stratify mice into
two groups: above and equal to or below median levels. A
significant difference in tumor-free survival was observed
between the two groups (Figure 8a), thus confirming that,
in huHER2-transgenic mice, cancer prevention required a
fast, high antibody response. Study of the antibody iso-
types showed that IgG1, IgG2a and IgG2b were well-cinated with empty vector (pVAX1) or with HuRT-DNA against
ratio of spleen to cancer cells was used. Data are mean ± SEM of five
uRT, chimeric human/rat HER2 plasmid electroporated vaccine.
Figure 6 Serum anti-huHER2 antibodies induced by periodic
vaccination of FVB-huHER2 mice with HER2-cell or HuRT-DNA.
See Methods section for details on vaccination cycles. Horizontal bar
represents the median value of each group. HuRT-DNA vaccine
group had significantly higher antibody levels than the HER2-cell
vaccine group at 4, 24 and 40 weeks of treatment (P < 0.05 by
Wilcoxon nonparametric test). HuRT, chimeric human/rat HER2
plasmid electroporated vaccine.
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Figure 8 Anti-huHER2 antibodies elicited by HuRT-DNA. (a)
Tumor-free survival in mice vaccinated with chimeric human/rat
HER2 plasmid electroporated vaccine (HuRT)-DNA stratified according
to anti-huHER2 levels above (high antibody (Ab) level) or equal to or
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type 1 IgG2 and type 2 IgG1 recognized syn-HER2 and
xeno-HER2 cancer cells with identical isotype patterns
(Figure 8b). Anti-huHER2 antibodies affected signaling
events downstream of HER2. Treatment of syn-HER2
cancer cells with HuRT-DNA-induced antisera caused a
significant decrease in pHER2 and pAKT (Figure 8c).
Antibodies elicited in tolerant hosts impair the growth of
human HER2-positive tumor cells in vivo
The results demonstrate that anti-human HER2 vaccines
elicited protective immune responses against mouse tu-
mors expressing huHER2. To further extend the scope
of these studies, we sought to determine whether the
antibodies elicited by our vaccines could also inhibit the
in vivo growth of human cancers expressing HER2.
The antitumoral effectiveness of high-level anti-huHER2
antibodies elicited by HuRT-DNA vaccine in tolerant
hosts was therefore tested according to their ability to
hamper the growth of human HER2-positive cancer cellsFigure 7 Interferon γ production by spleen cells of FVB-huHER2-
vaccinated mice. Mean ± SEM data are shown for each group (n= 3 to
6 mice per group). Spleen cells were cultured alone (spont) or in the
presence of huHER2-positive cancer cells of syngeneic (syn-HER2) or
xenogeneic (xeno-HER2) origin. *P≤ 0.05 vs. other groups. HuRT, chimeric
human/rat HER2 plasmid electroporated vaccine; IFN, interferon.
below (low antibody level) the median after the first vaccination cycle
(n = 5 mice per group). P < 0.05 between the two groups by Mantel-
Haenszel test. (b) Isotypes of anti-HER2 antibodies. Sera were
incubated with syngeneic or xenogeneic target cells (syn-HER2
and xeno-HER2, respectively), then indirect immunofluorescence
was performed with fluorescein-labeled secondary antibodies to detect
murine immunoglobulin (total Ig) or specific murine isotypes. (c) Anti-
huHER2 antibodies elicited by HuRT-DNA caused a decreased huHER2
signaling in syn-HER2 cells. U = untreated cells; M = cells treated for the
indicated times with sera from Mock-vaccinated mice; H = cells treated
for the indicated times with sera from mice vaccinated with HuRT-
DNA. Time of exposure to antisera is reported at the top of the figure.
Densitometric analysis was performed. Band intensity was normalized
over the corresponding actin, then the percentage decrease between
M and H after the same incubation time was calculated and is shown
under the corresponding H lane.
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i.p. injections of human HER2-positive SK-OV-3 cancer
cells developed peritoneal carcinomatosis that can be ac-
curately measured by the collection and weighing of dis-
sected tumor masses [21,27]. The weekly i.p. injection of
sera from HuRT-DNA-vaccinated mice significantly de-
creased peritoneal carcinomatosis (Figure 9); therefore,
anti-huHER2 antibodies elicited by DNA vaccine in toler-
ant hosts impair human HER2-positive cancer growth
in vivo in immunodeficient mice, even in the absence of
most cellular and cytokine responses.
Discussion
The FVB-huHER2 mouse, which is prone to the devel-
opment of autochthonous mammary tumors driven by
huHER2 expression, was used as a model with which to
study active immunological strategies targeting the hu-
man HER2 molecule in a tolerant host. Both a whole-
cell vaccine and a DNA vaccine succeeded in breaking
tolerance toward huHER2, eliciting high levels of anti-
huHER2 antibodies and resulting in a significant delay in
tumor onset. In addition to the prevention of huHER2-
driven carcinogenesis in the original host, antibodies
elicited by the HuRT-DNA vaccine inhibited the growth
of human tumors when passively administered to immu-
nodeficient mice bearing HER2-positive xenografts.
The first conclusion we can draw from these results is
that vaccines against the human wild-type HER2 can
break tolerance and efficiently inhibit mammary carcino-
genesis driven by wild-type huHER2. Most cancer immu-
noprevention studies reported to date were conducted
with mice transgenic for the rat homologue [5].
In the present work, the cell vaccine consisted of
human HER2-positive cancer cells combined with IL-12Figure 9 Inhibition of HER2-positive SK-OV-3 xenograft intraperi-
toneal growth in immunodeficient mice injected intraperitoneally
with sera from FVB-huHER2-vaccinated mice. Each point represents
the weight of all tumor masses grown intraperitoneally and dissected
from each mouse. Horizontal bar represents the median value of each
group. P = 0.05 by Wilcoxon nonparametric test. HuRT, chimeric
human/rat HER2 plasmid electroporated vaccine.administration. Therefore, xenogeneic antigens and IL-12
had an adjuvant effect able to break tolerance to HER2,
similarly to what we previously reported with regard to
the combination of allogeneic antigens and IL-12 [11,12].
The HER2-cell vaccine elicited both anti-huHER2 anti-
bodies and a strong IFN-γ response.
The DNA vaccine was engineered to encode a chimeric
human-rat HER2 protein and was coupled to in vivo elec-
troporation. Therefore, adjuvant effects of both xeno-
geneic HER2 sequences and electroporation broke the
immunological tolerance to huHER2, resulting in a very
high level of specific anti-huHER2 antibodies (in agree-
ment with previous studies [16,18]) coupled with a very
limited induction of IFN-γ. These results suggest that
an anti-HER2 DNA vaccine and electroporation could be
very advantageous in a clinical setting, yielding higher
antibody responses than whole-cell vaccines (possibly as a
result of lower local recruitment of Foxp3 regulatory T
cells) without the risk of high IFN-γ stimulation, as also
reported for work in different model systems [15]. In fact,
data on the safety of DNA anti-HER2 vaccines have been
reported in a pilot clinical trial [28].
The antitumor activity of anti-huHER2 antibodies elic-
ited in a nontolerant host is well-known; in fact, trastu-
zumab and other monoclonal antibodies used in human
therapy were originally obtained through immunization
of mice against the xenogeneic human HER2 molecule.
However, little is known about the antitumor activity of
antibodies against huHER2 elicited in a tolerant host.
Studies in rat HER2-transgenic mice have shown that
the break of immunological tolerance to HER2 was
based on the recognition of subdominant epitopes, be-
cause dominant clones had been selectively deleted [29].
A similar condition is likely to occur in humans, who
are naturally tolerant to endogenous HER2.
Are antibodies induced by the break of tolerance able to
inhibit tumor growth? We found that passive transfer of
antisera from DNA-vaccinated, FVB-huHER2-transgenic
mice to immunodeficient mice carrying xenografts of
HER2-positive human cancer cells inhibited human tumor
growth. The Rag2−/−;Il2rg−/− immunodeficient mice used
in our present study lacked the effectors mostly active in
antibody-dependent cellular cytotoxic (ADCC) responses,
(that is, natural killer (NK) cells), and could underestimate
the potential antibody efficacy obtainable in immunocom-
petent hosts. In these mice, however, other cytotoxic anti-
body functions can be active, such as ADCC responses by
leukocytes other than NK cells, complement-dependent
cytotoxicity and direct effects on signaling downstream
HER2.
Conclusions
The FVB-huHER2-transgenic mouse is a unique model
system that allows immunological studies of anti-human
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hosts prone to mammary carcinoma onset. The results re-
ported herein show that effective vaccinations break the im-
munological tolerance to human HER2 and elicit immune
responses, in particular antibodies, that inhibit the onset of
murine HER2-positive mammary carcinoma and inhibit
the in vivo growth of human HER2-positive cancer cells.
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